Histone deacetylase 2 (HDAC2) is relevant for homeostasis and plays a critical role in gastrointestinal cancers. Here, we report that post-translational modification of endogenous HDAC2 with small ubiquitin-related modifier 1 (SUMO1) is a new regulatory switch for the tumor suppressor p53. Sumoylation of HDAC2 at lysine 462 allows binding of HDAC2 to p53. Moreover, sumoylated HDAC2 is a previously not recognized biologically relevant site-specific deacetylase for p53. Deacetylation of p53 at lysine 320 by sumoylated HDAC2 blocks recruitment of p53 into promoter-associated complexes and p53-dependent expression of genes for cell cycle control and apoptosis. Thereby, catalytically active sumoylated HDAC2 restricts p53 functions and attenuates DNA damage-induced apoptosis. Genotoxic stress evokes desumoylation of HDAC2, enabling p53-dependent gene expression. Our data show a new molecular mechanism involving a dynamically controlled HDAC2-sumoylation/p53-acetylation switch that regulates cell fate decisions following genotoxic stress.
Introduction
Histone deacetylases (HDACs) are crucial regulators of gene expression, signaling, and homeostasis. These enzymes remove acetyl moieties from 1-N-acetylated lysine residues of histones and non-histone proteins. In higher eukaryotes, deacetylases are grouped into four classes. Class I deacetylases (HDAC1, 2, 3, and 8) are ubiquitously expressed and often show deregulated expression patterns in transformed cells. Class IIa (HDAC4, 5, 7, and 9) and IIb (HDAC6 and 10) enzymes are larger and their expression is restricted to certain cell types. HDAC11 belongs to class IV. Sirtuins (SIRT1-7), mammalian orthologs of yeast Sir2, comprise class III (Yang and Seto, 2008) .
The functions of HDACs are modulated by post-translational modifications (PTMs) (Brandl et al., 2009) . Recent findings reveal unique and isoenzyme-specific roles for HDAC2 that are controlled via PTMs (Krämer, 2009) . HDAC2 is subject to phosphorylation, ubiquitinylation, nitration, and nitrosylation.
Sumoylation is the covalent attachment of SUMO (small ubiquitin-related modifier) to lysine residues of proteins. Four SUMO proteins (SUMO1-4) have been identified in humans. Sumoylation occurs by an enzymatic cascade involving the E1-activating enzyme SAE1/2, the E2 SUMO-conjugase UBC9, and E3 SUMO-ligases enhancing sumoylation (Geiss-Friedlander and Melchior, 2007; Gareau and Lima, 2010) . SUMO-specific proteases (SENPs) deconjugate SUMO rendering sumoylation highly dynamic (Kim and Baek, 2009) . A link between sumoylation and the deacetylation machinery has been noticed (Ouyang and Gill, 2009 ) and the NAD + -dependent SIRT1 as well as HDAC1, 4, 6, and 9 can be sumoylated (Yang et al., 2007; Brandl et al., 2009) . Although SUMO modification of the three first mentioned enzymes was found necessary for full catalytic activity, others measured similar catalytic activities of sumoylated and nonsumoylated HDAC1 (Brandl et al., 2009) . It has also not been resolved whether sumoylation of class I HDACs can specifically affect their association with transcription factors. HDAC inhibitors (HDACi) block the catalytic activity of HDACs. Treatment with HDACi attenuates proliferation and evokes tumor cell apoptosis. Interestingly, HDACi affect the functions of the tumor suppressor protein p53 by increasing its acetylation (Terui et al., 2003; Zhao et al., 2006; Palani et al., 2012) . This and other modifications alter the capability of p53 to associate with chromatin and to induce the expression of its target genes that encode factors controlling cell cycle arrest and apoptosis. Cell cycle control genes are usually induced early and possess high-affinity p53 binding sites (e.g. p21). Pro-apoptotic gene expression is regulated by p53 via lower affinity p53-binding sites (e.g. BAX) and is induced upon persistent or strong stress (Vousden and Prives, 2009; Beckerman and Prives, 2010; Schneider and Krämer, 2011) .
It is unclear whether sumoylation of HDACs affects endogenous gene expression and how this may modulate p53 during the DNA damage response (DDR). Moreover, although the epigenetic regulator HDAC2 and the tumor suppressor p53 are discussed to have antagonistic functions with physiological relevance, the molecular mechanisms orchestrating their interplay still need to be defined. In this study we show that catalytically active endogenous HDAC2 can be modified by SUMO1 and that cell fate decisions depend on HDAC2 tagged with SUMO. We reveal that only sumoylated HDAC2 binds to and selectively deacetylates p53 at lysine 320 (K320) in genetically defined reconstituted cells. Consequently, this interferes with the DNA binding of p53 and alters the expression of endogenous p53 target genes. These processes ultimately impair the apoptotic response and increase the robustness of cells exposed to genotoxic stress. Our results identify dynamically controlled sumoylation of HDAC2 as a previously unrecognized regulatory switch for the tumor suppressor p53.
Results
Lysine 462 is essential for sumoylation of HDAC2 in vitro and in vivo Analyzing whole cell extracts from various cell lines with different anti-HDAC2 antibodies revealed a prominent HDAC2-reactive band at the expected size of 55-60 kDa and a slower migrating species ( Figure 1A and Supplementary Figure S1A) . The 15-20 kDa molecular weight shift of this band pointed to a PTM with ubiquitin-like factors, e.g. SUMO. To exclude that we detected a splice variant of HDAC2, we expressed HA-tagged HDAC2 in HEK293T cells. We again observed a higher molecular weight fraction with anti-HA antibodies ( Figure 1B) , suggesting that this slower migrating form indeed represents post-translationally modified HDAC2.
To test whether HDAC2 can be conjugated to SUMO, we employed an in vitro SUMO modification assay (Werner et al., 2009) . In vitro translated HDAC2 was incubated with recombinant SUMO1, SUMO-E1, and SUMO-E2 enzymes. In the presence of ATP, a single higher migrating HDAC2 band emerged. This protein fraction corresponded in size to SUMO1-modified HDAC2 ( Figure 1C ). Subsequently, we used immunoprecipitation (IP) with SUMO1-specific antibodies to probe for endogenously sumoylated HDAC2. Indeed, SUMO1-modified HDAC2 was detected in anti-SUMO1 precipitates from lysates of HCT116 human colon cancer cells ( Figure 1D ) and HEK293T human embryonic kidney cells (Supplementary Figure S1B) . In addition, SUMO1-HDAC2 was enriched in IPs compared with the input. Consistent with our in vitro data, one SUMO1-modified version of HDAC2 was observed. These findings suggest that endogenous HDAC2 is a bona fide substrate for modification with SUMO1.
Sumoylation usually occurs at lysine residues within the consensus sequence CKxE, where C represents a large hydrophobic amino acid, K is the modified lysine, x can be any amino acid, and E is glutamic acid (Geiss-Friedlander and Melchior, 2007) . Lysine 462 (K462) in the structurally flexible C-terminus is the only residue of HDAC2 within a CKxE motif. Comparison of HDAC2 from Pan troglodytes, Mus musculus, Rattus norvegicus, and Xenopus laevis revealed interspecies conservation of this sumoylation consensus sequence ( Figure 2A) . To test the relevance of K462 to HDAC2 sumoylation, we mutated K462 into a nonsumoylatable but charge-conserving arginine (HDAC2
K462R
) and generated a C-terminal deletion mutant lacking the last 28 amino acids including K462 (HDAC2 1 -460 ). In vitro translated HDAC2, HDAC2
, and HDAC2
1 -460 were subjected to in vitro sumoylation. Notably, wild-type HDAC2 was modified with SUMO1, but HDAC2 K462R and HDAC2 1 -460 remained unmodified (Supplementary Figure S1C) . To assess whether K462 is critical for sumoylation in vivo, HEK293T cells were transfected with V5-tagged HDAC2 or HDAC2
. Anti-V5 IPs contained a higher migrating form of HDAC2 which was absent in HDAC2 K462R precipitates ( Figure 2B ). Coexpression of SENP1, which recognizes and deconjugates SUMO from proteins (Kim and Baek, 2009) , led to disappearance of the slower migrating HDAC2 band. This effect was not observed when catalytically inactive SENP1 was cotransfected ( Figure 2B ). Also, SENP1 specifically coprecipitated only with wild-type HDAC2 but not with HDAC2 K462R ( Figure 2C ).
Finally, we performed anti-SUMO1 precipitates from lysates of HEK293T cells expressing V5-tagged HDAC2 or HDAC2 K462R .
Probing for HDAC2 showed sumoylation of the wild type but not of the K462R protein ( Figure 2D ). Taken together, these experiments show that K462 is strictly required for modification of HDAC2 with SUMO1. Next, we tested whether sumoylation of HDAC2 controls its general functions or whether this PTM has an effect on specific HDAC2 functions. Cell lines with defined genetic backgrounds lacking endogenous HDAC2 provide the opportunity to clearly discriminate between biological functions of HDAC2 and HDAC2
. RKO colon cancer cells lack HDAC2 (Ropero et al., 2008) . Screening for an additional cellular model revealed that HCT116 p53 2/2 colon cancer cells (Bunz et al., 1998) are also HDAC2-deficient (Supplementary Figure S2A) . We investigated whether HDAC2 sumoylation determines its intracellular targeting with immunofluorescence microscopy. In RKO cells, wild-type HDAC2 and sumoylation-deficient HDAC2 K462R and HDAC2 1-460 were strictly nuclear (Supplementary Figure S2B) . Thus, sumoylation of HDAC2 unlikely controls its nuclear localization. Next, we determined if the transcriptional repression capacities of HDAC2 are sumoylation dependent. A GAL4-driven luciferase reporter was employed with GAL4-HDAC2 or GAL4-HDAC2 K462R in HEK293T cells and HDAC2-negative HCT116 p53 2/2 cells. The latter was chosen to exclude an influence of endogenous HDAC2. Both HDAC2 variants suppressed reporter gene expression to a similar extent in both cell lines ( Figure 2E ). These data indicate equivalent repression by HDAC2 and HDAC2
when artificially tethered to a promoter. Contrary to other SUMO-modified deacetylases (Yang et al., 2007; Brandl et al., 2009 ), yet in agreement with our reporter gene assays, immunoprecipitated wild-type and sumoylationdeficient HDAC2 were similarly active in an in vitro deacetylase assay (Supplementary Figure S2C) . This finding agrees with sumoylation of HDAC2 at the far C-terminus, away from the central catalytic domain of the protein. Also, binding to the corepressor mSIN3a did not differ between HDAC2 and HDAC2 K462R (Supplementary Figure S2D) . A requirement of sumoylation for HDAC2 enzymatic capacity in vitro is therefore not supported by our data. Still, sumoylation of HDAC2 might have an effect towards specific in vivo targets by allowing or disrupting protein complex with these targets. Sumoylation though seems not to influence HDAC2 stability. IPs from HEK293T cells expressing HDAC2-V5 or HDAC2 K462R -V5 revealed equal interaction of HDAC2 with UBC8 and RLIM and both HDAC2 variants displayed similar degradation kinetics (Supplementary Figure S2D and E).
HDAC2 sumoylation modulates gene expression controlled by p53
What could be the relevance of HDAC2 sumoylation? To address this question, we stably reconstituted RKO cells with wild-type HDAC2-V5 or HDAC2 K462R -V5 to achieve a situation resembling endogenous HDAC2. Compensatory regulation of HDAC1/HDAC3 was not observed ( Figure 3A) . As in other cells, wild-type HDAC2-V5 underwent sumoylation while HDAC2 K462R -V5 did not (Supplementary Figure S3A) . Since HDAC2 can affect p53 functions (Harms and Chen, 2007; Ropero et al., 2008; Krämer, 2009; Li et al., 2010) , we investigated putative effects of HDAC2 sumoylation on p53 target gene expression. The cell cycle regulator CDKN1A (p21
), the pro-apoptotic factors PIG3 and BAX, as well as p53's major ubiquitin-E3 ligase HDM2 (human Mdm2) are positively regulated p53 target genes (Vousden and Prives, 2009) . Remarkably, we noticed drastically reduced levels of these proteins in RKO cells expressing wild-type HDAC2 compared with those with non-sumoylatable HDAC2 K462R ( Figure 3A ).
Cytoprotective Survivin (BIRC5) on the other hand is directly repressed by p53 (Schneider and Krämer, 2011; Xia et al., 2011) . Concordantly, Survivin levels were elevated in HDAC2 RKO cells compared with RKO cells harboring HDAC2 K462R ( Figure 3A) .
Quantitative real-time PCR-based mRNA expression analyses showed that downregulation of HDM2 and p21 in HDAC2 RKO cells corresponds to reduced mRNA levels ( Figure 3B) . Consistent with the lower expression of HDM2, p53 levels are elevated in cells carrying wild-type HDAC2 ( Figure 3A and Supplementary Figure S3B ). While mutations of p53 can cause its accumulation, RKO cells harbor wild-type p53 (Xia et al., 2011) , suggesting that reduced expression of HDM2 leads to increased wild-type p53 levels in RKO cells with wild-type HDAC2. Comparing the original mixed cell populations of stable RKO cells with single clones revealed similar expression profiles for the p53-inducible proteins mentioned above (Supplementary Figure S3B) . Therefore, our results are not limited to single clones. In sum, these results argue that functionally impaired p53 accumulates in cells with wild-type HDAC2. These results strongly indicate that sumoylated HDAC2 blocks p53-dependent target gene expression and that HDAC2 sumoylation interferes with positive and negative transcriptional regulation by p53.
To corroborate these findings, we transiently expressed HDAC2 and HDAC2
K462R in HCT116 cells. Consistent with our hypothesis of a sumoylation-dependent functionality of HDAC2 towards p53, only wild-type HDAC2 suppressed the p53-responsive reporter pRGC-Luc ( Figure 3C , left). This effect was p53-dependent as it was not present in HCT116 p53 2/2 cells ( Figure 3C, Figure S3C) . Thus, repression of p53-dependent transcription is mediated specifically by sumoylation-competent HDAC2.
Next, we tested whether p53 levels per se or HDAC activity cause the inert state of p53 in HDAC2-positive RKO. Incubation with Nutlin-3a, a specific inhibitor of HDM2 (Schneider and Krämer, 2011) , stabilized p53 and resulted in comparable p53 protein levels in RKO cells harboring wild-type HDAC2 or HDAC2 K462R ( Figure 3D ). This treatment promoted the expression of p21 and HDM2 in control and HDAC2 K462R RKO, but not in cells expressing wild-type HDAC2 ( Figure 3D, left) . Furthermore, increasing p53 levels by such treatment resulted in stronger repression of Survivin in HDAC2 K462R cells, while it was ineffective in wild-type HDAC2 cells. Thus, sumoylated HDAC2 seems to inactivate p53 regardless of its expression levels.
To test whether the catalytic activity of HDAC2 locks p53 in an inert state, we used the HDACi VPA which targets HDAC2 (Brandl et al., 2009) . In contrast to Nutlin-3a, VPA induced p21 expression in all stable RKO cells and decreased Survivin expression in cells carrying wild-type HDAC2 ( Figure 3D, right) . These data show that VPA restored p53 functionality regarding induction of p21 and repression of Survivin. The finding that VPA reduced HDM2 expression ( Figure 3D , right) reflects the described suppression of this promoter upon HDACi-induced hyperacetylation (Ropero et al., 2008; Ku et al., 2009) . Taken together, these experiments indicate that sumoylatable catalytically active HDAC2 antagonizes p53 functions. Whereas increasing the levels of p53 with Nutlin-3a cannot compensate for this effect, blocking the catalytic activity of sumoylatable HDAC2 with VPA restores p53-dependent transcription. HDAC2 is a previously not recognized sumoylation-dependent deacetylase for p53
Acetylation of several C-terminal lysine residues can influence p53-dependet apoptosis by increasing p53's DNA binding capacity, target gene selectivity and transcription-activating properties ( Tang et al., 2008) . This encouraged us to investigate a supposed HDAC2-dependent deacetylation of p53. Acetylation at K320 by the acetyltransferase p300/CBP-associated factor (PCAF) controls induction of p21 by p53 (Liu et al., 1999; Knights et al., 2006; Xenaki et al., 2008) . As we recognized strong effects of wild-type HDAC2 on p21 expression in RKO cells ( Figure 3A) , we focused on K320 acetylation. Indeed, PCAF-triggered acetylation of p53 K320 was reduced by HDAC2 and could be rescued by VPA treatment ( Figure 4A ). Using an in vitro deacetylase assay we additionally tested if purified HDAC2 can deacetylate purified p53 at K320. Overexpressed HA-tagged HDAC2 was immunoprecipitated and released from IP beads with free HA peptide. Incubation of immunoprecipitated p53 with the supernatant containing HA-HDAC2 caused strong deacetylation of p53 K320 (Supplementary Figure S3D ). These data demonstrate that HDAC2 is a previously not recognized deacetylase for p53. Consistent with these results, RKO cells with HDAC2 and highly increased p53 levels ( Figure 3A and D) did not exhibit augmented p53 K320 acetylation. When total p53 amounts in untreated cells were adjusted, p53 K320 was even much less acetylated in HDAC2-positive RKO cells compared with those harboring sumoylation-deficient HDAC2 K462R ( Figure 4B ). These data cannot be explained by different PCAF levels ( Figure 3A) . Importantly, wild-type HDAC2 deacetylated p53 K320 , whereas non-sumoylatable HDAC2 K462R was not able to deacetylate p53 at K320 ( Figure 4C) . We further examined the interaction of p53 with wild-type HDAC2 and HDAC2
K462R
. Western blot analyses of anti-p53 immunoprecipitates revealed that endogenous p53 readily interacts with HDAC2, but not with sumoylation-deficient HDAC2 ( Figure 4D ). These data argue for sumoylation as the molecular trigger directing HDAC2 against acetylation of p53 K320 .
HDAC2 sumoylation regulates stress-induced apoptosis by impeding acetylation and DNA binding of p53 Although the above data implicate sumoylated HDAC2 in the control of p53, they cannot prove that deacetylation of p53 by wild-type HDAC2 inactivates p53. To elucidate the functional consequences of HDAC2 on p53, avidin-biotin complex -DNA (ABCD) binding assays were used to test if the lower relative p53 K320 acetylation level in wild-type HDAC2 RKO cells prevents in vitro DNA binding of p53. HDAC2-RKO and HDAC2
-RKO cells were treated with Nutlin-3a to achieve equal levels of p53. Two independent p53-binding site oligonucleotides captured less p53 from RKO cells expressing HDAC2 compared with RKO cells with HDAC2
( Figure 5A ). We further performed chromatin-IP (ChIP) analyses to evaluate the role of sumoylated HDAC2 for p53 promoter-specific DNA binding in vivo. Recruitment of p53 to the p21 and HDM2 promoters in wild-type HDAC2 cells was strongly reduced when compared with HDAC2 K462R cells ( Figure 5B ). These experiments suggest that HDAC2 deacetylates p53 to inhibit its recruitment to different promoters encoding physiologically relevant genes. Both, HDAC2 and p53 regulate the proliferation and survival of normal and cancer cells under genotoxic stress (Krämer, 2009; Vousden and Prives, 2009) . We tested whether sumoylation of HDAC2 determines apoptosis in the context of DNA damage caused by doxorubicin. This drug induces double-strand DNA breaks and causes p53-dependent apoptosis (Schneider and Krämer, 2011; Xia et al., 2011) . Of note, flow cytometric analyses disclosed that RKO cells expressing the wild-type HDAC2 were significantly less susceptible to doxorubicin-induced apoptosis compared with RKO cells reconstituted with sumoylation-deficient HDAC2 K462R ( Figure 5C ). Dead cells with a DNA content below 2N (sub-G1) were 20% for RKO cells with the wild-type HDAC2 and 70% for RKO cells with HDAC2 K462R (P , 0.001).
Additionally, cotreatment of HDAC2 K462R -V5 RKO cells with a lower dose of doxorubicin and Nutlin-3a led to markedly enhanced apoptosis (Supplementary Figure S3E) pointing out that enhanced p53 levels in the presence of genotoxic stress greatly enhance apoptosis in cells reconstituted with HDAC2 K462R . In perfect agreement with our hypothesis that sumoylated HDAC2 blocks p53-dependent gene expression ( Figure 3D ), wild-type HDAC2-positive cells are less sensitive to this drug combination (Supplementary Figure S3E ). These data demonstrate that sumoylated wild-type HDAC2 attenuates p53-dependent apoptosis in cells exposed to DNA damage. Nonetheless, HDAC2-positive cells undergo apoptosis in response to doxorubicin, and we also see a significantly lower but discernable effect of doxorubicin on HDAC2-positive cells ( Figure 5C ). Based on these findings and on the fact that stress alters sumoylation patterns within cells (Gareau and Lima, 2010) , we hypothesized that HDAC2 sumoylation is a dynamically controlled upstream regulator of p53. Remarkably, HDAC2 became desumoylated upon genotoxic exposure of cells ( Figure 5D ). Treatment of RKO-HDAC2-V5 cells results in a drastic increase in p53 and p21 expression ( Figure 5E ), hinting that HDAC2 desumoylation after genotoxic stress allows transcriptional competence of p53.
Taken together, our data suggest that sumoylation of HDAC2 is a dynamic regulator for p53-dependent gene expression and cell fate decisions.
Discussion
In this article, we show that HDAC2 is covalently modified with SUMO1. We demonstrate that an intact CKxE sumoylation consensus motif around lysine 462 of HDAC2 is essential for this modification. The fact that this consensus motif is evolutionarily conserved from Xenopus to humans points to a biologically important role of HDAC2 sumoylation. We reveal that sumoylationdeficient HDAC2 does not interact with p53, whereas sumoylation-competent HDAC2 does. Our new finding that modification with SUMO controls the HDAC2 interactome is a major conceptual advance. Upon analyzing the biological consequences of HDAC2 sumoylation, we noticed that disrupting this sitespecific PTM has a strong impact on p53-dependent gene expression in transformed human cells. We found that HDAC2 can inhibit p53-dependent induction of p21, PIG3, BAX, and HDM2, as well as p53-dependent suppression of Survivin.
In search for the molecular relay underlying the control of p53 by HDAC2, we discovered that HDAC2 is a p53 deacetylase. PCAF-triggered p53 K320 acetylation promotes binding of p53 to its consensus sites in vitro and to the p21 promoter in vivo (Liu et al., 1999; Knights et al., 2006; Xenaki et al., 2008) . We reveal here that HDAC2 binds to p53 and reverses its acetylation at K320. Both processes strictly depend on sumoylation of HDAC2. In line with this, we detect impaired acetylation of p53 K320 together with strongly diminished binding of p53 to the p21 and HDM2 promoters in cells positive for wild-type HDAC2. Of note, this is not the case in cells carrying sumoylation-deficient HDAC2. Reduced amounts of HDM2, the major ubiquitin ligase for p53, might contribute to the accumulation of p53 we noticed. It is noteworthy that p53 in the wild-type HDAC2 reconstituted cells is hypoacetylated and consequently not able to modulate steady-state levels of p53 target genes.
Hypoacetylated p53 could even cause dominant-negative effects as tetramer formation is required for the functionality of p53 as a transcription factor (Chan et al., 2004) . Therefore, we speculate that reduced acetylation of p53 K320 , located near the DNA-binding domain and the tetramerization domain of p53 (Beckerman and Prives, 2010) , generates inactive p53 tetramers which may account for the pronounced DNA-binding deficiency of p53 in cells expressing wild-type HDAC2 (Figure 6 ). Albeit the amount of sumoylated species represents only a fraction of total HDAC2, our data reveal that this pool has unique and privileged biological functions. Similar results were collected for the majority of sumoylation targets. Furthermore, it is well known that sumoylation engages permissive states for complex formation and protein functions (Hay, 2005; Geiss-Friedlander and Melchior, 2007) . Studies on HDAC sumoylation often rely on reporter assay systems and cells carrying the endogenous protein. This strategy can be problematic as sumoylation affects only a subset of protein species (Hay, 2005; Geiss-Friedlander and Melchior, 2007) . An advance of our work is the analysis of HDAC2 functions in genetically defined reconstituted null backgrounds. Our data indicate that HDAC2 sumoylation at K462 establishes a switch for its association with p53 and deacetylation of p53 K320 . HDAC1 and SIRT1 have also been described as p53 deacetylases, but do not target p53 K320 (Beckerman and Prives, 2010) . Remarkably, only sumoylated SIRT1 triggers deacetylation of p53 K382 and SIRT1 sumoylation also affects p53-independent apoptosis (Yang et al., 2007) . Similar to the regulation of p53 by SIRT1, only sumoylation-competent HDAC2 leads to decreased p53 K320 acetylation in our cell system. Data supporting a crucial role of HDAC2 for p53-dependent gene expression were also collected in murine fibroblasts lacking the ubiquitin ligase Mule which degrades HDAC2 (Zhang et al., 2011) . Moreover, knocking down HDAC2 induces the p21 and HDM2 genes due to enhanced p53 promoter binding (Harms and Chen, 2007) . Our work links HDAC2-and SUMO-dependent mechanism to reduced endogenous p53-dependent gene expression and apoptosis. Overall, our results are consistent with studies revealing negative effects of the epigenetic regulator HDAC2 on p53 (Harms and Chen, 2007; LeBoeuf et al., 2010; Li et al., 2010; Wilting et al., 2010; Zhang et al., 2011) . We extend these studies as we delineate a previously unrecognized molecular mechanism that connects p53 with HDAC2. It should also be considered that p53 can be dynamically regulated by methylation, phosphorylation, and other PTMs (Knights et al., 2006; Huang et al., 2007; Beckerman and Prives, 2010) . For example the methyltransferase Set7/9 promotes an increase in p53 acetylation levels in cells exposed to genotoxic stress (Liu et al., 2011) . It will be interesting to find out whether this mechanism is associated with HDAC sumoylation. Furthermore, it is possible that HDAC2 deacetylates p53 at additional lysine residues in a cell-type and stimulusdependent fashion. Such complex regulatory circuits should be investigated in future studies.
Expression of the pro-apoptotic proteins PIG3 and BAX is repressed by wild-type HDAC2, which deacetylates p53 K320 .
Accordingly, cells carrying a p53 K320R mutant are resistant to apoptosis (Terui et al., 2003) . However, p53 K317R knock-in mice (murine K317 corresponds to human K320) can transactivate pro-apoptotic target genes (Chao et al., 2006) . Independent of cell-type/context-dependent effects, human cells carrying sumoylated HDAC2 have low p21 levels that could facilitate tumor proliferation. While BAX and PIG mediate p53-dependent apoptosis, HDM2 provides a negative feed-back on p53 stability to permit the survival of stressed cells (Brooks and Gu, 2006) . Suppression of HDM2 in HDAC2 wild-type cells allows p53 accumulation, which is potentially dangerous for cells. Deacetylation by HDAC2 compensates this effect by impairing the transcription factor p53 and the expression of its tumor suppressive target genes. Dysregulation of HDAC2 and p53 in numerous human malignancies indeed implies that the balanced activity of both factors is required for cellular homeostasis (Olsson et al., 2007; Krämer, 2009) . Numerous cancers, including colon tumors, overexpress HDAC2 which promotes their survival and proliferation (Fritsche et al., 2009; Krämer, 2009; Weichert, 2009; Fakhry et al., 2010) . Moreover, HDAC2 is an independent prognostic marker in colorectal carcinomas and oral cancers (Huang et al., 2005; Weichert et al., 2008; Chang et al., 2009 ). The present data suggest that a selection for high HDAC2 levels in some cancer types bypasses the potent tumor suppressor p53 without the need for inactivating p53 mutations. We show that colon cancer cells expressing sumoylation-deficient HDAC2, i.e. HDAC2 unable to deacetylate p53, are much more sensitive to DNA damage-induced apoptosis than cells expressing wild-type Figure 6 HDAC2 sumoylation regulates p53 activities. Catalytically active sumoylatable HDAC2 locks the tumor suppressor p53 in an inactive state. The mechanism by which HDAC2 negatively controls p53-dependent transcription relies on the ability of HDAC2 to become sumoylated at K462. Consequently, HDAC2 binds to and deacetylates p53 at K320 which strongly attenuates its DNA binding. This process suppresses the expression of the pro-apoptotic factors BAX and PIG3, of the cell cycle regulator p21 and of the E3 ubiquitin-ligase HDM2. It also blocks the p53-mediated transcriptional repression of the anti-apoptotic protein Survivin (Surv). This ultimately modulates the apoptotic response to genotoxic stress.
HDAC2. Thus, sumoylation of HDAC2 and not its mere presence appear as relevant marker for the control of p53 and the (patho-) physiological role of HDAC2.
Chemotherapy-induced genotoxic stress reduces HDAC2 sumoylation and allows p53-dependent target gene expression. However, cells with sumoylated HDAC2 have already less basal p53-dependent gene expression and are accordingly more resistant against DDR-induced apoptosis. We speculate that inactivation of p53 by aberrantly expressed HDAC2 is perhaps an early necessary step for cell transformation. The importance of HDAC activity in the control of p53 is stressed by studies showing increased p53 acetylation and p53-dependent gene expression after treatment of cells with HDACi (Terui et al., 2003; Roy et al., 2005; Zhao et al., 2006; Lin et al., 2008; Palani et al., 2012) . We provide a mechanistic explanation for these observations and extend the knowledge on PTMs and the crosstalk of the epigenetic and transcriptional regulators HDAC2 and p53.
Materials and methods
Cell culture, transfections, cell extracts, IP and western blotting Cells were maintained in Dulbecco's modified Eagle's medium containing 2% L-glutamine (PAA Laboratories, now GE Healthcare) supplemented with 10% fetal calf serum (Sigma-Aldrich). Experimental details on western blotting and IPs and buffer composition, drugs, chemicals, plasmids and antibodies can be found in Supplementary material.
Luciferase assays
Details for this method are listed in Supplementary material. In vitro sumoylation assays V5-tagged HDAC2, HDAC2 K462R, and HDAC2 1-460 were expressed in vitro using the TNT w T7 Coupled Reticulocyte Lysate System (Promega). Sumoylation assays using 1 ml TNT-Lysate per reaction were performed as described (Werner et al., 2009) . Generation of stable RKO cell lines HDAC2-negative RKO cells were transfected with plasmids encoding GFP, V5-tagged wild-type HDAC2, and HDAC2 K462R , respectively, on two successive days. Cells were treated with 800 mg/ml G418 (PAA) to select transfectants.
ABCD assays
Experimental details on ABCD assays can be found in Supplementary material. Quantitative real-time PCR Details for this method can be found in Supplementary material.
Flow cytometry
Cells were treated with doxorubicin 1 day after seeding. Cells were detached with accutase (PAA), washed with PBS (PAA) and fixed (70% EtOH, 2208C; at least 1 h). DNA was stained with 10 mM propidium iodide, 38 mM sodium citrate, and 100 mg/ml RNaseA (Roth) for 30 min. Measurements were performed with an FACSCanto Flow Cytometer and FACSDiVa software (BD).
Chromatin IP
Chromatin IP (ChIP) was performed as stated (Baus et al., 2009) . For p53-ChIPs, mouse a-p53 (DO-1; Santa Cruz) was used. Determination of the amount of precipitated DNA was done by RT-qPCR in principle as described above. Primer sequences are given in Supplementary Table S1 .
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
